AAN's First 21st-Century Position Statement on Ethical Consideration in Dementia Diagnosis and Care

The Editor retracts this editorial1 at the request of the author because the author’s views on the topic are no longer reflected in the editorial in light of the FDA’s approval of the drug aducanumab for use in treatment of Alzheimer disease. The FDA approved the drug on June 7, 2021, after the editorial was submitted (February 25, 2021) or accepted in final form by Neurology (March 4, 2021) but before it was published (July 13, 2021).

Read article at journal's website

Related Articles


Your email address will not be published.